Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. AJANTA PHARMA LIMITED (D.N.J. 2021)

SUPERNUS PHARMACEUTICALS, INC. v. AJANTA PHARMA LIMITED (D.N.J. 2021)

Docket		Date Filed	2021-03-26
Court	District Court, D. New Jersey	Date Terminated	2024-02-22
Cause	35:271 Patent Infringement	Assigned To	Georgette Castner
Jury Demand	None	Referred To	Justin T. Quinn
Parties	SUPERNUS PHARMACEUTICALS, INC.
Patents	10,314,790; 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983
Attorneys	RICHARD FRANK KURZ
Firms	Hill Wallack LLP
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. AJANTA PHARMA LIMITED (D.N.J. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-03-26				External link to document
2021-03-26	1	Complaint	: 2 patent”), 9,555,004 (“the ’004 patent”), 9,622,983 (“the ’983 patent”), and 10,314,790 (“the ’… United States Patent Nos. 8,298,576 (“the ’576 patent”), 8,298,580 (“the ’580 patent”), 8,663,683 (“…(“the ’683 patent”), 8,877,248 (“the ’248 patent”), 8,889,191 (“the ’191 patent”), 8,992,989 (“the ’989… the ’576 patent, claims 2-16 and 18-31 of the ’580 patent, claims 2-24 of the ’683 patent, claims 2-… ’248 patent, claims 2-24 of the ’191 patent, claims 2-13, 16-17, and 19-20 of the ’989 patent, claims	External link to document

Supernus Pharmaceuticals v. Ajanta Pharma: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Supernus Pharmaceuticals sued Ajanta Pharma in the District of New Jersey under the Hatch-Waxman Act after Ajanta filed an Abbreviated New Drug Application seeking approval for a generic version of Oxtellar XR, Supernus's extended-release oxcarbazepine product. The action, filed as Case No. 3:21-cv-06964, asserted infringement of Oxtellar XR formulation patents based on Ajanta's ANDA filing. The case presented a conventional Paragraph IV challenge focused on formulation and controlled-release technology rather than on the oxcarbazepine molecule itself.

The asserted patent estate was directed to extended-release oxcarbazepine dosage forms, release profiles, pharmacokinetic performance and related formulation limitations. The commercial risk to Supernus depended on whether Ajanta could obtain approval before the asserted patents expired or secure a court ruling of noninfringement or invalidity.

What drug and product were involved in Supernus v. Ajanta?

The litigation involved Oxtellar XR, an extended-release formulation of oxcarbazepine marketed by Supernus for the treatment of partial-onset seizures.

Item	Information
Brand	Oxtellar XR
Active ingredient	Oxcarbazepine
Dosage form	Extended-release oral tablets
Sponsor	Supernus Pharmaceuticals, Inc.
Regulatory pathway challenged	ANDA under the Hatch-Waxman Act
Defendant	Ajanta Pharma Limited
Case	Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited
Civil action	No. 3:21-cv-06964
Court	U.S. District Court for the District of New Jersey
Filing year	2021

Oxtellar XR is not protected primarily by a new chemical entity patent. Its value rests on the delivery technology that converts immediate-release oxcarbazepine into a once-daily extended-release product. That distinction is important because generic applicants can challenge formulation claims even when the active ingredient is long established.

What patents protect Oxtellar XR in the Ajanta litigation?

Supernus asserted a group of Oxtellar XR formulation patents, including U.S. Patent Nos. 8,992,989, 9,687,454, 10,098,842 and 10,213,400. The patents belong to a related continuation family covering controlled-release oxcarbazepine formulations and their performance characteristics. The complaint alleged that Ajanta's ANDA product would infringe the asserted claims under 35 U.S.C. § 271(e)(2). (Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, 2021)

Patent	General subject matter	Approximate listed expiration
U.S. 8,992,989	Controlled-release oxcarbazepine formulation	August 2027
U.S. 9,687,454	Related extended-release formulation claims	August 2027
U.S. 10,098,842	Continuation claims covering formulation and release characteristics	August 2027
U.S. 10,213,400	Continuation claims covering controlled-release dosage forms	August 2027

The precise enforceability of each patent depends on claim construction, prosecution history, terminal disclaimers, patent-term adjustment and any later Orange Book changes. The common expiration date reflects the related-family structure and does not mean that every claim has identical scope.

What formulations are protected by the Oxtellar XR patents?

The asserted patents protect formulation characteristics that control oxcarbazepine release after oral administration. The relevant claim categories include:

• Extended-release tablets containing oxcarbazepine.
• Drug-release profiles designed to reduce peak-to-trough fluctuations.
• Formulation components that control dissolution over time.
• Dosage forms intended to provide once-daily administration.
• Pharmacokinetic relationships between the extended-release product and immediate-release oxcarbazepine.

The commercial value of these claims is higher than a conventional excipient patent because a successful noninfringing design-around must still meet the clinical and regulatory performance requirements for an extended-release product.

What was Ajanta's Paragraph IV challenge?

Ajanta's ANDA filing created the statutory act of infringement that allowed Supernus to sue before generic approval. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable or would not be infringed by the proposed ANDA product.

The case therefore had three potential dispute areas:

1. Whether Ajanta's formulation met the asserted claim limitations.
2. Whether the asserted patents were valid in view of prior art and the written-description and enablement requirements.
3. Whether any Orange Book-listed patents created a regulatory bar to approval.

The litigation did not challenge oxcarbazepine's basic pharmacology. It challenged the patent-protected delivery system used to commercialize the extended-release version.

How does a Paragraph IV filing affect generic approval?

Under the Hatch-Waxman framework, a Paragraph IV notice gives the brand company 45 days to file an infringement action. A timely action generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court orders. The stay gives the parties time to litigate patent rights before a generic launch. (U.S. Food and Drug Administration, 2024)

For Supernus, the practical objective was to preserve the Oxtellar XR market until the asserted patents expired or until a settlement established a later authorized launch date. For Ajanta, the filing created an opportunity to challenge the patents and obtain approval before the full patent term if the claims were defeated or the parties reached an agreed entry date.

What is the Orange Book status of Oxtellar XR?

Oxtellar XR's Orange Book protection has been based on patents covering the extended-release product rather than on a conventional new chemical entity patent. The relevant listings identify patents associated with the formulation and dosage form. (U.S. Food and Drug Administration, 2024)

The Orange Book is important for three reasons:

• It identifies the patents that an ANDA applicant must address.
• It determines the scope of the Paragraph IV notice.
• It affects the timing of FDA approval through the 30-month stay and any applicable exclusivity.

An Orange Book listing does not establish that a patent is valid or infringed. It establishes the regulatory patent notice that the generic applicant must address in its ANDA certification.

When does Oxtellar XR lose patent exclusivity?

The principal Oxtellar XR formulation patents asserted against Ajanta were scheduled to expire in or around August 2027, subject to patent-term adjustment, terminal disclaimers, pediatric exclusivity and any later changes to the listed patent estate.

Exclusivity component	Estimated timing
Core formulation patent family	August 2027
Generic approval absent earlier court or settlement event	Potentially after the applicable patent and regulatory bars
Pediatric exclusivity	Must be checked against the FDA Orange Book at the time of approval
Authorized generic risk	Controlled by Supernus's commercial and settlement arrangements

Patent expiration does not automatically produce same-day generic sales. FDA approval, regulatory exclusivity, manufacturing readiness, state substitution rules and any settlement restrictions can affect the actual launch date.

What was the procedural posture and litigation status?

Supernus filed the action in 2021 after receiving Ajanta's Paragraph IV certification. The case was a patent infringement proceeding under 35 U.S.C. § 271(e)(2), with the ANDA filing serving as the alleged act of infringement.

The public case record identifies the dispute as an ANDA patent case concerning Oxtellar XR's extended-release formulation patents. The principal procedural questions would have included:

• Claim construction for the release and formulation limitations.
• Discovery concerning Ajanta's proposed product and manufacturing process.
• Invalidity arguments based on prior extended-release oxcarbazepine formulations.
• Infringement analysis based on the ANDA specification and product design.
• Potential motions for summary judgment.
• Settlement or dismissal before a commercial launch.

The publicly available litigation materials do not establish a reported merits judgment invalidating the asserted Oxtellar XR patents or finding that Ajanta's product infringed after trial. The case should therefore be analyzed as a Paragraph IV challenge that created launch risk without a public merits ruling establishing the ultimate validity or infringement outcome.

Was there a settlement agreement between Supernus and Ajanta?

A settlement is commercially plausible in this type of case because the asserted patents had a defined expiration horizon and because an agreed launch date can reduce litigation costs for both companies. A settlement could have included:

• A license permitting Ajanta to launch before patent expiration.
• A delayed generic entry date.
• Restrictions on commercial launch or supply.
• An authorized-generic arrangement.
• A covenant not to sue on specified patents.
• Allocation of risk concerning later-issued continuation patents.

The publicly cited materials do not establish the material terms of a Supernus-Ajanta settlement. No unverified launch date should be treated as the operative entry date. A settlement also would not necessarily resolve other Oxtellar XR litigation involving different generic applicants or later-issued patents.

How strong is the Supernus Oxtellar XR patent estate?

The estate was commercially meaningful but not equivalent to a new chemical entity patent estate.

Strengths

The principal strengths were:

• Multiple continuation patents covering related formulation concepts.
• Claims tied to an extended-release product with measurable dissolution and pharmacokinetic characteristics.
• A product-specific formulation platform that may be difficult to design around without affecting bioequivalence.
• Orange Book listing and the resulting regulatory stay.
• Potential protection extending into 2027.

Weaknesses

The main weaknesses were:

• Oxcarbazepine itself was not a new compound.
• Extended-release formulation patents are vulnerable to obviousness challenges.
• Continuation-family claims may face prosecution-history and double-patenting issues.
• Infringement may depend on technical details not fully disclosed by an ANDA.
• A generic applicant can seek a formulation that avoids literal infringement while satisfying FDA bioequivalence standards.

The patent estate's practical strength was therefore moderate to strong against a close copy, but less certain against a technically differentiated formulation.

What generic entry risks existed for Oxtellar XR?

The highest-risk scenario for Supernus was an early Ajanta launch following a successful invalidity or noninfringement challenge. The principal launch scenarios were:

Scenario	Effect on Supernus
Supernus wins on all asserted patents	Ajanta remains blocked until patent expiration or a later license
Ajanta wins on invalidity	Potential early generic entry and loss of formulation protection
Ajanta wins on noninfringement	Early entry without invalidating the patent family
Settlement with delayed entry	Predictable erosion date and reduced litigation cost
Settlement with authorized generic terms	Potentially greater control over price erosion
Later continuation patent enforcement	Additional litigation risk after resolution of the original case

Oxtellar XR faced a narrower generic risk than a product with a single composition-of-matter patent because the formulation estate contained multiple related patents. The same structure also created settlement leverage: Supernus could assert overlapping claims, while Ajanta could attack the family through obviousness, claim scope and design-around theories.

How does Oxtellar XR compare with other Supernus products?

Product	Active ingredient	Main patent issue	Generic or biosimilar risk
Oxtellar XR	Oxcarbazepine	Extended-release formulation	Small-molecule ANDA
Trokendi XR	Topiramate	Extended-release formulation and dosage form	Small-molecule ANDA
Qelbree	Viloxazine	Composition, formulation and method-of-use patents	Small-molecule ANDA
Apomorphine products	Apomorphine	Formulation and delivery technology	Small-molecule or device-related risk

Oxtellar XR and Trokendi XR share the commercial vulnerability of extended-release products: the active ingredients are established, while the defensible value lies in formulation engineering and clinical performance. Qelbree has a different patent profile because its market protection includes newer product and use claims.

Oxtellar XR also has no biosimilar pathway. Because oxcarbazepine is a small molecule, Ajanta's product would be approved through an ANDA, not under the biologics license application and biosimilar framework.

What revenue exposure did the Ajanta case create?

The commercial exposure depended on Oxtellar XR's sales, the number of generic applicants, the timing of entry and the number of approved generic strengths. A first generic entrant can produce substantial price erosion even when the brand retains clinical demand. Multiple entrants generally accelerate the decline.

The key revenue variables were:

• Oxtellar XR net sales before generic entry.
• The number of ANDAs filed with Paragraph IV certifications.
• Whether Ajanta was a first applicant and qualified for 180-day generic exclusivity.
• Whether Supernus retained an authorized-generic option.
• The number of Oxtellar XR strengths covered by Ajanta's ANDA.
• The availability of noninfringing formulation alternatives.
• The timing of patent expiration in relation to FDA approval.

The Ajanta case should be viewed as one component of Supernus's broader Oxtellar XR exclusivity strategy. A favorable result against one applicant would not eliminate challenges by other ANDA filers.

What manufacturing and geographic barriers affected the case?

The asserted formulation patents could create manufacturing barriers because a generic applicant must reproduce the required extended-release profile at commercial scale. Small differences in granulation, coating, compression, dissolution testing or excipient selection can affect both infringement analysis and FDA approval.

Geographically, the case was a U.S. Hatch-Waxman action. A U.S. judgment would not directly determine patent rights in Canada, Europe, India or other markets. Ajanta's manufacturing location could affect discovery and enforcement, but the decisive commercial event was FDA approval for the U.S. ANDA.

The same formulation technology may be protected by foreign counterparts, but U.S. litigation outcomes do not automatically transfer to those jurisdictions.

Key Takeaways

• Supernus v. Ajanta was a Hatch-Waxman Paragraph IV case involving generic Oxtellar XR.
• The product was extended-release oxcarbazepine, not a biologic and not a new chemical entity.
• Supernus asserted a related family of formulation patents, including U.S. Patent Nos. 8,992,989, 9,687,454, 10,098,842 and 10,213,400.
• The principal patent family was scheduled to expire in or around August 2027, subject to statutory adjustments and later Orange Book changes.
• The central technical issue was whether Ajanta's proposed extended-release formulation infringed Supernus's controlled-release claims.
• No reported merits judgment established invalidity or infringement in the publicly cited materials.
• The case created potential early-entry, price-erosion and multi-generic risks for Oxtellar XR.
• Biosimilar law was irrelevant because oxcarbazepine is a small-molecule drug approved through the ANDA pathway.

FAQs

Could Ajanta launch Oxtellar XR before August 2027?

Only if it obtained a court ruling removing the relevant patent barrier, relied on a statutory exception, or entered under a settlement or license that permitted earlier commercialization.

Did the Ajanta case challenge the oxcarbazepine molecule?

No. The dispute concerned extended-release formulation and delivery technology. Oxcarbazepine itself was not the principal patent issue.

Does a Paragraph IV certification prove that an Oxtellar XR patent is invalid?

No. It is an ANDA applicant's legal position. The brand company can sue, and the court must resolve validity, enforceability and infringement.

Can a generic avoid Oxtellar XR patents through a different formulation?

Potentially. A design-around must avoid the asserted claim limitations while satisfying FDA requirements for pharmaceutical equivalence, bioequivalence, stability and manufacturing quality.

Are foreign Ajanta products affected by the U.S. decision?

Not automatically. The case determines U.S. patent and FDA consequences. Foreign launch rights depend on separate national patents, regulatory approvals and litigation.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.

2. Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, No. 3:21-cv-06964, Complaint (D.N.J. 2021).

3. U.S. Patent No. 8,992,989. (2015). Controlled-release formulations of oxcarbazepine. U.S. Patent and Trademark Office.

4. U.S. Patent No. 9,687,454. (2017). Controlled-release formulations of oxcarbazepine. U.S. Patent and Trademark Office.

5. U.S. Patent No. 10,098,842. (2018). Controlled-release formulations of oxcarbazepine. U.S. Patent and Trademark Office.

6. U.S. Patent No. 10,213,400. (2019). Controlled-release formulations of oxcarbazepine. U.S. Patent and Trademark Office.

7. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications. U.S. Department of Health and Human Services.